GSK's Vaccines Chief Slaoui To Follow Witty Out The Door

One person definitely not lining up to take over from Sir Andrew Witty when he retires from GlaxoSmithKline PLC in March 2017 is its vaccines chief and former head of R&D Dr. Moncef Slaoui. He is to retire from the company in June 2017.

Moncef Slaoui
Moncef Slaoui • Source: GSK

Slaoui spearheaded the overhaul of GlaxoSmithKline PLC pharmaceutical R&D and was instrumental in its DPU (discovery performance unit) initiative. Like Andrew Witty, Moncef Slaoui has spent the bulk of his career at GSK in a variety of roles spanning 28 years. (Also see " Witty Succumbs To Pressure: GSK Starts Formal Search For New CEO " - Scrip, 18 March, 2016.)

Prior to his current role as chairman of vaccines, where he oversaw the integration with the Novartis AG vaccines...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.